podcasts

Highlights of the AAPS 2024 Summer Scientific Forum

Posted: 21 October 2024 | | No comments yet

In this episode, we discuss the history of the AAPS Summer Scientific Forum, highlights from the 2024 event, and its goals for the future.

In this podcast episode, titled ‘Highlights of the AAPS 2024 Summer Scientific Forum’, we will be discussing the conferences’ history, as well as its goals for the future.

This conversation features Lynn Kamen, Scientific Officer, Executive Director at BioAgilytix, and Sachin Lohani, Executive Director at Eli Lilly and Company.

Key discussion points:

  • What differentiates this AAPS conference from both NBC and PharmSci 360
  • Key presentation highlights from the 2024 Forum, including:
    • The implementation of new technologies for bioanalysis
    • Analytical approaches for novel modalities, such as macrocyclic peptides, small proteins, lipid nanoparticles, and charged variants.
  • How the Forum fosters community with their scientific attendees

About the speakers

Lynn Kamen, Scientific Officer, Executive Director at BioAgilytix

Lynn KamenLynn Kamen is a Scientific Officer at BioAgilytix. She earned her PhD in Immunology at the University of Michigan and completed a postdoctoral fellowship in immunology at the University of California San Francisco. Lynn has over a decade of experience working in drug development, from early target discovery through clinical development for both large and small molecules at several companies including Portola Pharmaceuticals, and Alector. More recently, Lynn was a principal scientist at Genentech where she supported the in vitro biological characterisation of large molecules and led the development of immunogenicity assays including ADA, NAb and immunogenicity risk ranking assays. She is co-lead of the AAPS NAb working group.

Sachin Lohani, Executive Director at Eli Lilly and Company

Sachin LohaniSachin Lohani, PhD, is currently serving as Director Analytical Research & Development, Merck Research Laboratories. His group supports analytical characterisation of drug substance and drug product from early development to commercialisation. Sachin received his PhD in Pharmaceutics from University of Minnesota. He started his professional career in 2006 at Merck and held positions with increasing responsibilities within various organisations in MRL. In 2014, he joined FDA’s Office of Pharmaceutical Science as a CMC reviewer and then served as a Policy Analyst/Acting Branch Chief in the Office of Policy in Pharmaceutical quality. After his tenure at FDA, he joined Jansen Pharmaceuticals (Johnson & Johnson), where he established the group responsible for conducting developability assessment of discovery compounds at the Spring House PA site. Prior to his current role, Sachin was serving as director of pharmaceutical development at Celgene, where he was responsible for leading cross-functional pharmaceutical development teams responsible for meeting CMC milestones from Phase I through registration.

 

Leave a Reply

Your email address will not be published. Required fields are marked *